What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress

View Full Paper

Ask AI

Bookmark

Investigate safety and tolerability of switching from emicizumab to fitusiran in severe hemophilia A.
Exploratory, open-label, single-arm Phase 1 study
Approximately 15-20 adult males with severe hemophilia A
Washout period followed by fitusiran prophylaxis
Monitor adverse events over 4 months after starting fitusiran
Assess thrombin generation and antithrombin levels
Evaluate quality of life and bleeding rates during treatment

No takes yet. Share an insight, caveat, or question.

Exploratory trial assesses safety and tolerability of fitusiran prophylaxis in males with hemophilia A, indicating safe transition from emicizumab.

Young et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Exploratory trial assesses safety and tolerability of fitusiran prophylaxis in males with hemophilia A, indicating safe transition from emicizumab.